A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency
A Phase 2, Single-Arm Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This research study is a Phase II clinical trial. This study will assess the safety and tolerability of denosumab in Multiple Myeloma participants, by studying drug interactions with different parts of the body.
The FDA (the U.S. Food and Drug Administration) has not approved Denosumab for this specific disease but it has been approved denosumab for use in other cancers to treat cancer-related bone disease such as prostate and breast cancer.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Elizabeth K O'Donnell, MD
- Phone Number: 617-724-4000
- Email: ekodonnell@partners.org
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Danvers, Massachusetts, United States, 01923
- Mass General/North Shore Cancer Center
-
Newton, Massachusetts, United States, 02462
- Newton Wellesley Hospital
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Hospitals of Cleveland
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients with symptomatic MM as defined by IMWG requiring anti-myeloma therapy.
- Monoclonal plasma cells in the bone marrow greater than or equal to 10% and/or presence of a biopsy-proven plasmacytoma
- Monoclonal protein present in the serum and/or urine
- Creatinine clearance < 30 mL/min, not eligible for bisphosphonate. Estimated glomerular filtration rate will be calculated using Cockcroft-Gault equation.
- Serum calcium or albumin-adjusted serum calcium ≥ 2.1 mmol/L (8.4 mg/dL) and ≤ 2.9 mmol/L (11.5 mg/dL) (Reference range 8.5-10.8 mg/dL)
- Able to tolerate daily supplementation of calcium and vitamin D
- Vitamin D level ≥ 30 ng/mL after repletion
Participants must have normal organ as defined below:
- Total bilirubin ≤ 2.0 x ULN
- AST(SGOT) ≤2.5 × institutional upper limit of normal
- ALT(SGPT) ≤2.5 × institutional upper limit of normal
- Plan to receive anti-myeloma therapies.
- Age ≥ 18 years.
- ECOG performance status ≤ 2
- Life expectancy greater than 6 months
- 0-3 lines of prior anti-myeloma therapy.
- Subjects with reproductive potential must be willing to use, in combination with his/her partner, 2 highly effective methods of effective contraception or practice sexual abstinence throughout the study and continue for 5 months after the study duration. Subjects who are surgically sterile (e.g. history of bilateral tubal ligation, hysterectomy) or whose sexual partner is sterile (e.g. history of vasectomy) are not required to use additional contraceptive measures.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Prior administration of denosumab.
- Active IV bisphosphonate use in the last 3 months.
- POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
- Plasma cell leukemia.
- Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw.
- Active dental or jaw condition which requires oral surgery, including tooth extraction.
- Non-healed dental/oral surgery, including tooth extraction.
- Planned invasive dental procedures during the course of study.
Evidence of any of the following conditions per subject self-report or medical chart review
- Any prior invasive malignancy within 5 years of enrollment that may affect outcome of study
- Any non-invasive malignancy not treated with curative intent or with known active disease within 5 years before enrollment that may affect outcome of study
- Major surgery or significant traumatic injury occurring within 4 weeks before enrollment
- Active infection with Hepatitis B virus or Hepatitis C virus
- known infection with human immunodeficiency virus (HIV)
- Active infection requiring IV anti-infective therapy
- Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after the end of treatment.
- Female subject of child-bearing potential is not willing to use, in combination with her partner, 2 methods of highly effective contraception during treatment and for 5 months after the end of treatment.
- Clinically significant hypersensitivity to denosumab 120 mg.
- Known sensitivity to any of the products to be administered during the study (e.g. calcium, or vitamin D).
- Subject is receiving or is less than 14 days since ending other experimental drug (no marketing authorization for any indication).
- Any major medical or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Denosumab Injection
Patients will be administered Denosumab Q4W at a pre-determine dose for 12 cycles.
Denosumab Q4W is administered by subcutaneous injection.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent Change Of sCTX Levels
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent Change In Bone Mineral Density
Time Frame: 2 years
|
2 years
|
|
Percent Change In uNTX Levels
Time Frame: 2 years
|
2 years
|
|
Subject Incidence Of Hypocalcemia
Time Frame: 2 years
|
2 years
|
|
Subject Incidence Of Occurrence Of Documented SRE At 12 Months
Time Frame: 2 years
|
2 years
|
|
Subject Incidence Of Adverse Events
Time Frame: 2 years
|
2 years
|
|
Percent Change In Bone Turnover Markers
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Elizabeth K O'Donnell, MD, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Neoplasms
- Immune System Diseases
- Neoplasms by Histologic Type
- Hematologic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Neoplasms, Plasma Cell
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Hemorrhagic Disorders
- Hemic and Lymphatic Diseases
- Multiple Myeloma
- Amino Acids, Peptides, and Proteins
- Proteins
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Antibodies
- Immunoglobulins
- Immunoproteins
- Blood Proteins
- Serum Globulins
- Globulins
- Denosumab
Other Study ID Numbers
Other Study ID Numbers
- 15-571
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.